Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding
Public Deposited- Creator
- Trimble, A.
-
McKinzie, C.
- Eshelman School of Pharmacy
- Terrell, M.
-
Stringer, E.
- School of Medicine, Department of Obstetrics and Gynecology
-
Esther, C.R., Jr
- School of Medicine, Cystic Fibrosis and Pulmonary Diseases Research and Treatment Center
- Abstract
- With the growing class of CFTR modulator therapy available to more patients and with increasing pregnancies in individuals with CF, there is a growing need to understand the effects of these agents during pregnancy. There are few reports of their continued use in the literature, although it is likely that this is not an uncommon occurrence. We report the uncomplicated and successful pregnancy of a woman treated with lumacaftor/ivacaftor, as well as the clinical course of the infant during the first 9 months of life. We also report drug levels in plasma from the mother, cord blood, breast milk, and infant to estimate fetal and infant drug exposure.
- Date of publication
- 2018
- Keyword
- DOI
- Identifier
- PMID 29866531
- https://dx.doi.org/10.1016/j.jcf.2018.05.009
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- Journal of Cystic Fibrosis
- Journal volume
- 17
- Journal issue
- 6
- Page start
- 779
- Page end
- 782
- Language
- English
- ISSN
- 1569-1993
- Publisher
- Elsevier B.V.
Relations
- Parents:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
1-s2.0-S1569199318305915-main.pdf | 2020-09-01 | Public | Download |